PGS Publication: PGP000047

Publication Information (EuropePMC)
Title Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.
PubMed ID 29321194(Europe PMC)
doi 10.1136/bmj.j5757
Publication Date Jan. 10, 2018
Journal BMJ
Author(s) Seibert TM, Fan CC, Wang Y, Zuber V, Karunamuni R, Parsons JK, Eeles RA, Easton DF, Kote-Jarai Z, Al Olama AA, Garcia SB, Muir K, Grönberg H, Wiklund F, Aly M, Schleutker J, Sipeky C, Tammela TL, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokolorczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Cuk K, Saum KU, Park JY, Sellers TA, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Karow DS, Mills IG, Andreassen OA, Dale AM, PRACTICAL Consortium*.
Released in PGS: Feb. 12, 2020

Associated Polygenic Score(s)

PGS Developed By This Publication

Polygenic Score (PGS) ID PGS Name PGS Publication (PGP) ID Reported Trait Mapped Trait(s) (Ontology) Number of Variants PGS Scoring File (FTP Link)
PGS000067 PCa_PHS PGP000047 Seibert TM et al. BMJ (2018) Prostate cancer prostate carcinoma 54 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000067/ScoringFiles/PGS000067.txt.gz

PGS Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance Metric ID
(PPM ID)
Evaluated Score PGS Sample Set ID
(PSS ID)
Performance Source Trait PGS Effect Sizes
(per SD change)
PGS Classification Metrics Other Metrics Covariates Included in the Model PGS Performance: Other Relevant Information
PPM000186 PGS000067 (PCa_PHS) PSS000107 PGP000047
Seibert TM et al. (2018)
Reported Trait: very aggressive prostate cancer HR (Hazard ratio; top 2% vs. average risk): 3.0[2.2, 4.0]
PPM000187 PGS000067 (PCa_PHS) PSS000107 PGP000047
Seibert TM et al. (2018)
Reported Trait: very aggressive prostate cancer (age at onset) z-test (p-value) < 1e-11
PPM000185 PGS000067 (PCa_PHS) PSS000106 PGP000047
Seibert TM et al. (2018)
Reported Trait: any prostate cancer (age at onset) z-test (p-value) < 1e-16
PPM000184 PGS000067 (PCa_PHS) PSS000106 PGP000047
Seibert TM et al. (2018)
Reported Trait: any prostate cancer HR (Hazard ratio; top 2% vs. average risk): 2.5[2.2, 2.8]
PPM000182 PGS000067 (PCa_PHS) PSS000105 PGP000047
Seibert TM et al. (2018)
Reported Trait: aggressive prostate cancer HR (Hazard ratio; top 2% vs. average risk): 2.9[2.4, 3.4]
PPM000183 PGS000067 (PCa_PHS) PSS000105 PGP000047
Seibert TM et al. (2018)
Reported Trait: aggressive prostate cancer (age at onset) z-test (p-value) < 1e-16

Evaluated Samples

PGS Sample Set ID
(PSS ID)
Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000105 Men screened with PSA testing, who did not receive a diagnosis of prostate cancer. 4,828 individuals,
100.0 % Male samples
Mean = 59.0 years
Iqr = [55.0, 63.0] years
European ProtecT
PSS000105 Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of aggressive prostate cancer (defined as any of Gleason score ≥7, stage T3-T4, PSA concentration ≥10 ng/mL, nodal metastasis, or distant metastasis)
[
  • 628 cases
]
,
100.0 % Male samples
Mean = 64.3 years
Iqr = [60.2, 67.5] years
European ProtecT
PSS000106 Men screened with PSA testing, who did not receive a diagnosis of prostate cancer. 4,828 individuals,
100.0 % Male samples
Mean = 59.0 years
Iqr = [55.0, 63.0] years
European ProtecT
PSS000106 Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of prostate cancer.
[
  • 1,583 cases
]
,
100.0 % Male samples
Mean = 63.4 years
Iqr = [59.0, 67.5] years
European ProtecT
PSS000107 Men screened with PSA testing, who did not receive a diagnosis of prostate cancer. 4,828 individuals,
100.0 % Male samples
Mean = 59.0 years
Iqr = [55.0, 63.0] years
European ProtecT
PSS000107 Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of very aggressive prostate cancer (defined as any of Gleason score ≥8, stage T3-4, positive nodes, or distant metastases)
[
  • 220 cases
]
,
100.0 % Male samples
European ProtecT